{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:56:58Z","timestamp":1790888218855,"version":"4.1.0"},"reference-count":28,"publisher":"Universidad Nacional de C\u00f3rdoba","issue":"3","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Fac Cien Med Univ Nac Cordoba"],"abstract":"<jats:p>Introduction: Inborn Errors of Metabolism (IEM) are rare diseases that affect multiple systems and require strict treatment adherence. However, maintaining adherence is a challenge that directly impacts the quality of life (QoL) of patients and their families.\nObjective: To review treatment adherence in patients with IEM or their caregivers, considering its relationship with QoL. Methods: A systematic review was conducted in PubMed following PRISMA guidelines. Articles in English and Spanish published between 2013 and 2024 were included. Results: Twenty-two studies were selected, most focused on phenylketonuria (PKU). The main barriers to adherence were lack of disease understanding, treatment burden and complexity, limited access to special foods and substitutes, economic impact, social stigma, and reduced adherence during adolescence and adulthood. Facilitators included family and social support, resilience, disease education, and home-based care. Adequate adherence was associated with better metabolic control, reduced neurological impact, and physical, emotional, and social benefits, while poor adherence negatively affected all QoL dimensions.\nConclusions: Treatment adherence in IEM is a complex process influenced by individual, family, social, and health system factors. Strengthening psychosocial and educational support, as well as improving access to resources, is essential to optimize adherence and QoL.<\/jats:p>","DOI":"10.31053\/1853.0605.v83.n3.50013","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:11:12Z","timestamp":1790885472000},"page":"e50013","source":"Crossref","is-referenced-by-count":0,"title":["Revisi\u00f3n sistem\u00e1tica sobre la adherencia al tratamiento en personas con Errores Cong\u00e9nitos del Metabolismo y sus familias","Systematic review on treatment adherence in people diagnosed with Inborn Errors of Metabolism and their families","Revis\u00e3o sistem\u00e1tica sobre ades\u00e3o ao tratamento em pessoas com diagn\u00f3stico de erros inatos do metabolismo e suas fam\u00edlias"],"prefix":"10.31053","volume":"83","author":[{"given":"Morena","family":"Bossie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0056-9806","authenticated-orcid":false,"given":"Florencia","family":"Assalone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0740-891X","authenticated-orcid":false,"given":"Javiera","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"12333","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. El-Hattab AW. Inborn Errors of Metabolism. Clinics in Perinatology. junio de 2015;42(2):413-39. doi: 10.1016\/j.clp.2015.02.010.","DOI":"10.1016\/j.clp.2015.02.010"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Walterfang M, Bonnot O, Mocellin R, Velakoulis D. The neuropsychiatry of inborn errors of metabolism. J of Inher Metab Disea. julio de 2013;36(4):687-702. doi: 10.1007\/s10545-013-9618-y.","DOI":"10.1007\/s10545-013-9618-y"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. P\u00e9rez-L\u00f3pez J. Terapia g\u00e9nica en el tratamiento de los errores cong\u00e9nitos del metabolismo [Gene therapy for the treatment of inborn errors of metabolism]. Med Clin (Barc). 2014 Jun 16;142(12):549-53. Spanish. doi: 10.1016\/j.medcli.2013.05.030.","DOI":"10.1016\/j.medcli.2013.05.030"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Bravo J P, Castro C H G. Actualizaci\u00f3n en el manejo agudo de errores cong\u00e9nitos del metabolismo [Update on acute management of inborn errors of metabolism]. Rev Chil Pediatr. 2014 Jul;85(4):421-7. Spanish. doi: 10.4067\/S0370-41062014000400003.","DOI":"10.4067\/S0370-41062014000400003"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Casti\u00f1eras DE, Couce ML, Marin JL, Gonz\u00e1lez-Lamu\u00f1o D, Rocha H. Situaci\u00f3n actual del cribado neonatal de enfermedades metab\u00f3licas en Espa\u00f1a y en el mundo [Newborn screening for metabolic disorders in Spain and worldwide]. An Pediatr (Engl Ed). 2019 Aug;91(2):128.e1-128.e14. Spanish. doi: 10.1016\/j.anpedi.2019.05.007.","DOI":"10.1016\/j.anpedi.2019.05.007"},{"key":"ref5","unstructured":"6. Reyes-Flores, E., Trejo-Alvarez, R., Arguijo-Abrego, S., J\u00edmenez-G\u00f3mez, A., Castillo-Castro, A., Hern\u00e1ndez-Silva, A., & Mazzoni-Ch\u00e1vez, L. Adherencia terap\u00e9utica: conceptos, determinantes y nuevas estrategias. Rev. M\u00e9d. Hond. 15 de diciembre de 2016;84(3-4):125-32."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Borghi L, Moreschi C, Toscano A, Comber P, Vegni E. The PKU & ME study: A qualitative exploration, through co-creative sessions, of attitudes and experience of the disease among adults with phenylketonuria in Italy. Mol Genet Metab Rep. 2020 Apr 2;23:100585. doi: 10.1016\/j.ymgmr.2020.100585.","DOI":"10.1016\/j.ymgmr.2020.100585"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Sundstrom R, Wetherill L, Sapp K, McPheron M, Lah M. Relationship satisfaction in adults with phenylketonuria is positively associated with following recommended treatment, having a partner involved in management, and maintaining good health. J Community Genet. 2023 Dec;14(6):627-638. doi: 10.1007\/s12687-023-00667-7.","DOI":"10.1007\/s12687-023-00667-7"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Firman SJ, Ramachandran R, Whelan K. Knowledge, perceptions and behaviours regarding dietary management of adults living with phenylketonuria. J Hum Nutr Diet. 2022 Dec;35(6):1016-1029. doi: 10.1111\/jhn.13015","DOI":"10.1111\/jhn.13015"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Green B, Browne R, Firman S, Hill M, Rahman Y, Kaalund Hansen K, Adam S, Skeath R, Hallam P, Herlihy I, Jenkinson F, Nicol C, Adams S, Gaff L, Donald S, Dawson C, Robertson L, Fitzachary C, Chan H, Slabbert A, Dunlop C, Cozens A, Newby C, Bittle V, Hubbard G, Stratton R. Nutritional and Metabolic Characteristics of UK Adult Phenylketonuria Patients with Varying Dietary Adherence. Nutrients. 2019 Oct 14;11(10):2459. doi: 10.3390\/nu11102459.","DOI":"10.3390\/nu11102459"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Medford E, Hare DJ, Carpenter K, Rust S, Jones S, Wittkowski A. Treatment Adherence and Psychological Wellbeing in Maternal Carers of Children with Phenylketonuria (PKU). JIMD Rep. 2017;37:107-114. doi: 10.1007\/8904_2017_23.","DOI":"10.1007\/8904_2017_23"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Didycz B, Bik-Multanowski M. Dynamics of hyperphenylalaninemia and intellectual outcome in teenagers with phenylketonuria. Acta Biochim Pol. 2017;64(3):527-31. doi: 10.18388\/abp.2017_1524.","DOI":"10.18388\/abp.2017_1524"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Witalis E, Mikoluc B, Motkowski R, Sawicka-Powierza J, Chrobot A, Didycz B, Lange A, Mozrzymas R, Milanowski A, Nowacka M, Piotrowska-Depta M, Romanowska H, Starostecka E, Wierzba J, Skorniewska M, Wojcicka-Bartlomiejczyk BI, Gizewska M, Car H; Polish Society of Phenylketonuria. Phenylketonuria patients' and their parents' knowledge and attitudes to the daily diet - multi-centre study. Nutr Metab (Lond). 2017 Aug 17;14:57. doi: 10.1186\/s12986-017-0207-1.","DOI":"10.1186\/s12986-017-0207-1"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Barta AG, Sum\u00e1nszki C, Turgonyi Z, Kiss E, Simon E, Serf\u0151z\u0151 C, Reismann P. Health Related Quality of Life assessment among early-treated Hungarian adult PKU patients using the PKU-QOL adult questionnaire. Mol Genet Metab Rep. 2020 Apr 22;23:100589. doi: 10.1016\/j.ymgmr.2020.100589.","DOI":"10.1016\/j.ymgmr.2020.100589"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Becsei D, Hiripi R, Kiss E, Szatm\u00e1ri I, Arat\u00f3 A, Reusz G, Szab\u00f3 AJ, B\u00f3kay J, Zsidegh P. Quality of life in children living with PKU - a single-center, cross-sectional, observational study from Hungary. Mol Genet Metab Rep. 2021 Nov 16;29:100823. doi: 10.1016\/j.ymgmr.2021.100823.","DOI":"10.1016\/j.ymgmr.2021.100823"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Beghini M, Pichler M, Tinnefeld FC, Metz M, M\u00f6slinger D, Konstantopoulou V, Spenger J, Kautzky-Willer A, Frommlet F, Scherer T, Hufgard-Leitner M. Poor adherence during adolescence is a risk factor for becoming lost-to-follow-up in patients with phenylketonuria. Mol Genet Metab Rep. 2024 May 9;39:101087. doi: 10.1016\/j.ymgmr.2024.101087.","DOI":"10.1016\/j.ymgmr.2024.101087"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Teruya KI, Remor E, Schwartz IVD. Factors that increase risk for poor adherence to phenylketonuria treatment in Brazilian patients. Am J Med Genet A. 2021 Jul;185(7):1991-2002. doi: 10.1002\/ajmg.a.62195.","DOI":"10.1002\/ajmg.a.62195"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Vieira E Neto, Maia HS Filho, Monteiro CB, Carvalho LM, Tonon T, Vanz AP, Schwartz IVD, Ribeiro MG. Quality of life and adherence to treatment in early-treated Brazilian phenylketonuria pediatric patients. Braz J Med Biol Res. 2017 Dec 11;51(2):e6709. doi: 10.1590\/1414-431X20176709.","DOI":"10.1590\/1414-431x20176709"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Mainka T, Fischer JF, Huebl J, Jung A, Lier D, Mosejova A, Skorvanek M, de Koning TJ, K\u00fchn AA, Freisinger P, Ziagaki A, Ganos C. The neurological and neuropsychiatric spectrum of adults with late-treated phenylketonuria. Parkinsonism Relat Disord. 2021 Aug;89:167-175. doi: 10.1016\/j.parkreldis.2021.06.011.","DOI":"10.1016\/j.parkreldis.2021.06.011"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Chiesa A, Sp\u00e9cola N, Poubel M, Vela-Amieva M, Jurecki E, Vilela DR, Mesojedovas D, Carneiro GC, Eiroa H, Nakamura KH, de Almeida ML, Cunha RB, Amorim T, Schwartz IVD. Adherence to PKU guidelines among patients with phenylketonuria: A cross-sectional national multicenter survey-based study in Argentina, Brazil, and Mexico. Mol Genet Metab Rep. 2023 Nov 21;38:101026. doi: 10.1016\/j.ymgmr.2023.101026.","DOI":"10.1016\/j.ymgmr.2023.101026"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, Benmedjahed K, Regnault A. Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries. Orphanet J Rare Dis. 2015 Jun 18;10:80. doi: 10.1186\/s13023-015-0294-x.","DOI":"10.1186\/s13023-015-0294-x"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Garc\u00eda MI, Araya G, Coo S, Waisbren SE, de la Parra A. Treatment adherence during childhood in individuals with phenylketonuria: Early signs of treatment discontinuation. Mol Genet Metab Rep. 2017 Apr 28;11:54-58. doi: 10.1016\/j.ymgmr.2017.04.006.","DOI":"10.1016\/j.ymgmr.2017.04.006"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Iakovou K, Schulpis K. The significant role of educational status in PKU patients: the beneficial effect of psychological support in depression. Int J Adolesc Med Health. 2019 Mar 19;33(4). doi: 10.1515\/ijamh-2018-0233.","DOI":"10.1515\/ijamh-2018-0233"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Poloni S, Dos Santos BB, Chiesa A, Specola N, Pereyra M, Sabor\u00edo-Rocafort M, Salazar MF, Leal-Witt MJ, Castro G, Pe\u00f1aloza F, Wong SP, Porras RB, Paranza LO, Sanabria MC, Amieva MV, Morales M, Naranjo ARC, Mahfoud A, Colmenares AR, Lemes A, Sotillo-Lindo JF, Perez C, Rey LM, Torriente GMZ, Refosco LF, Schwartz IVD, Cornejo V. Current Practices and Challenges in the Diagnosis and Management of PKU in Latin America: A Multicenter Survey. Nutrients. 2021 Jul 27;13(8):2566. doi: 10.3390\/nu13082566..","DOI":"10.3390\/nu13082566"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Rocha JC, Ahring KK, Bausell H, Bilder DA, Harding CO, Inwood A, Longo N, Muntau AC, Pessoa ALS, Rohr F, Sivri S, Hermida \u00c1. Expert Consensus on the Long-Term Effectiveness of Medical Nutrition Therapy and Its Impact on the Outcomes of Adults with Phenylketonuria. Nutrients. 2023 Sep 11;15(18):3940. doi: 10.3390\/nu15183940.","DOI":"10.3390\/nu15183940"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Cazzorla C, Bensi G, Biasucci G, Leuzzi V, Manti F, Musumeci A, Papadia F, Stoppioni V, Tummolo A, Vendemiale M, Polo G, Burlina A. Living with phenylketonuria in adulthood: The PKU ATTITUDE study. Mol Genet Metab Rep. 2018 Jul 11;16:39-45. doi: 10.1016\/j.ymgmr.2018.06.007.","DOI":"10.1016\/j.ymgmr.2018.06.007"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Didycz B, Bik-Multanowski M. Blood phenylalanine instability strongly correlates with anxiety in phenylketonuria. Mol Genet Metab Rep. 2017 Dec 27;14:80-82. doi: 10.1016\/j.ymgmr.2017.12.003.","DOI":"10.1016\/j.ymgmr.2017.12.003"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Toscano A, Musumeci O, Sacchini M, Ravaglia S, Siciliano G, Fiumara A, Verrecchia E, Maione M, Gentile J, Fischetto R, Crescimanno G, Taurisano R, Sechi A, Gasperini S, Cianci V, Maggi L, Parini R, Lupica A, Scarpa M. Safety outcomes and patients' preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond. Orphanet J Rare Dis. 2023 Oct 27;18(1):338. doi: 10.1186\/s13023-023-02919-8.","DOI":"10.1186\/s13023-023-02919-8"}],"container-title":["Revista de la Facultad de Ciencias M\u00e9dicas de C\u00f3rdoba"],"original-title":[],"link":[{"URL":"https:\/\/revistas.unc.edu.ar\/index.php\/med\/article\/download\/50013\/55956","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistas.unc.edu.ar\/index.php\/med\/article\/download\/50013\/55956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:13:26Z","timestamp":1790885606000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistas.unc.edu.ar\/index.php\/med\/article\/view\/50013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.31053\/1853.0605.v83.n3.50013","relation":{},"ISSN":["1853-0605","0014-6722"],"issn-type":[{"value":"1853-0605","type":"electronic"},{"value":"0014-6722","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}